Vistagen to present fasedienol (ph94b) safety and exploratory efficacy data from phase 3 open-label social anxiety disorder study at american society for clinical psychopharmacology annual meeting

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced that safety and exploratory efficacy data from its phase 3 open-label study of fasedienol (ph94b) nasal spray for the treatment of adults with social anxiety disorder (sad) will be presented in a late-breaking poster prese.
VTGN Ratings Summary
VTGN Quant Ranking